✦ Teva Pharmaceuticals USA, Inc. launched the first generics of Gilead Sciences, Inc.’s Truvada (emtricitabine/tenofovir disoproxil fumarate) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate). Emtricitabine/tenofovir disoproxil fumarate is indicated for the treatment of HIV-1 in combination with other antiretroviral agents in people weighing at least 37 pounds, as well as for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk people weighing at least 77 pounds. Efavirenz/emtricitabine/tenofovir disoproxil fumarate is indicated for the treatment of HIV-1 infection in people weighing at least 88 pounds either as a complete regimen or in combination with other antiretroviral agents. The wholesale acquisition cost for a tablet of 200 mg/300 mg emtricitabine/tenofovir disoproxil fumarate is $48.51 — or $1,455.30 for 30 days — and 600 mg/200 mg/300 mg efavirenz/emtricitabine/tenofovir disoproxil fumarate’s WAC is $78.86 per tablet, or $2,365.80 for 30 days. Website Drugs.com lists the price of 30 tablets of all four dosages of Truvada as $1,932.84, and the price of 30 600 mg/200 mg/300 mg tablets of Atripla as $3,135.98. Teva has savings cards for both drugs for eligible commercially insured patients available for download; the offers expire March 29, 2021. Visit www.tevahivgenerics.com.
✦ The United States realized $2.2 billion in savings from biosimilar use in 2019, according to the Association for Accessible Medicines report Securing Our Access & Savings: 2020 Generic Drug & Biosimilars Access & Savings in the U.S. Report. The total savings from 2010 to 2019 was almost $4.5 billion. But with 28 biosimilars approved and only 17 on the market, those delayed launches have cost the U.S. health system $9.8 billion in lost savings since 2015, according to the report, which was published Sept. 29. Download it at https://accessiblemeds.org/2020-Access-Savings-Report.